Key Takeaway: Lilly reported a 39% increase in Q3 2026 revenue, reaching $24.4 billion, primarily driven by Mounjaro and Zepbound. The quarter also included $900 million in benefits, largely from Jardiance milestones. The company raised its full-year guidance, reflecting strong performance across its portfolio.
Market Sentiment Analysis
POSITIVE FACTORS
Q3 2026 revenue increased 39% to $24.4 billion.
Mounjaro and Zepbound significantly contributed to revenue growth.
$900 million in benefits from Jardiance milestones.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+36%
120-day peak, hindsight
Typical move
1.3%
average across 15 past catalysts
Lead asset
Orforglipron
Phase 3 · Hypertension
Full Press Release Details
Revenue in Q3 2026 increased 39% to $24.4 billion driven primarily by Mounjaro and Zepbound. Q3 revenue included approximately $900 million of benefits, primarily from $410 million of Jardiance milestones (no further milestones remain) and favorable adjustments to rebate and discount estimates.
Frequently Asked Questions
What was Lilly's revenue for Q3 2026?
Lilly reported a revenue of $24.4 billion for Q3 2026.
What contributed to Lilly's revenue growth?
Mounjaro and Zepbound were the primary drivers of revenue growth.
What benefits did Lilly report in Q3 2026?
Lilly reported approximately $900 million in benefits from Jardiance milestones.
Did Lilly raise its full-year guidance?
Yes, Lilly raised its full-year guidance following strong Q3 results.